Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based CEO’ operating in the Pharmaceutical space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Furquan Kidwai
Founder & CEO of Dawaai
Furquan Kidwai is an entrepreneur building a pharmacy for emerging Asia. Prior to this journey, Kidwai was an investment banker for over eight years in London where, in his last role, he was the Head of CEEMEA Financing as well as a Senior Vice President in the Fixed Income business at the Royal Bank of Scotland. Before joining RBS, Mr. Kidwai worked at Merrill Lynch and Lehman Brothers in their London and New York offices. Mr. Kidwai has a Master’s degree in International Relations from Cambridge University. He also holds an MSc in Financial Engineering & Risk Management from Imperial College London and BEng (Hons) in Electrical and Computer Engineering from the University of Bristol.
Follow Furquan Kidwai:
About Dawaai: Dawaai operates as a digital health platform with an online network of pharmacies and generic medicine.
_______
John Lucas
Chief Executive Officer of Oxford Cannabinoid Technologies
John is a pharmaceutical executive with over 20 years of experience, having previously held executive level management positions at Cizzle Biotechnology (as CEO), Silence Therapeutics (as General Counsel) and Ilika Plc (Vice President, Intellectual Property) with other experience at the National Cancer Institute and Boehringer Ingelheim Pharma. John has also run his own consulting business where he assisted clients with business and legal/patent matters in biotech-pharma. His experience includes deal-making, corporate and product strategy, operations, and patents. John also has a wide range of subject matter experience including small molecule pharmaceuticals (including cannabinoids), RNA therapy, biologics, and diagnostics. John holds a law degree (JD) from George Washington University, a doctorate in molecular genetics from The Ohio State University, and a Master’s and Undergraduate degree in microbiology from Ohio University.
Follow John Lucas:
About Oxford Cannabinoid Technologies: OCT is a biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.
Alex Blyth
CEO of LIfT BioSciences
Serial entrepreneur with 15 years’ experience in commercialising biopharma assets and strategy consulting, having advised teams and led the strategic planning on the launch of over 50 assets. Founded the company after losing his mother to Pancreatic Cancer.
Follow Alex Blyth:
About LIfT BioSciences, NGX: LIfT BioSciences is a socially-minded Biotech start-up that develops a portfolio of potentially life-saving immuno-oncology cell therapies.
Avi Lasarow
CEO Europe, Middle East & Africa of Prenetics
Avi Lasarow is a multiple award-winning South African entrepreneur referred to by the media as ‘a lifestyle genetics pioneer’ known for his work associated with DNA testing. Avi is currently founder and CEO of genetic testing company DNAFit Life Sciences, which conducted the worlds 1st peer-reviewed and published clinical trial using both genetics and exercise interventions. In 2011 he became the youngest person to be appointed Honorary Consul for South Africa to the United Kingdom by His Excellency President Jacob Zuma. Avi was recently named African Businessman of the year in London at the African Enterprise Awards, his company DNAFit has won numerous awards, including the Lloyd’s Bank National Business Award for Innovation of the Year in 2015, winner at the UKActive Flame Awards and an award for Innovation at the South African Chamber Awards. Most recently, DNAFit was named as one of Fast Company’s Most Innovative in the field of Data Science.
Follow Avi Lasarow:
About DNAFit, Prenetics: Prenetics is a genetic and diagnostic health testing company that helps identify health risks with the use of a DNA sequencing technology.
Clive Dix
CEO of C4X Discovery
Clive Dix is the Chief Executive Officer at C4X Discovery Holdings plc. since November 2015. Clive has over thirty years’ experience in the pharmaceutical and biotechnology industries. Clive was Co-Founder and Chief Executive Officer of PowderMed Limited, which was sold to Pfizer Inc. in 2006 and Co-Founder and Chief Executive Officer of Convergence Pharmaceuticals Limited, which was sold to Biogen Inc. in 2015. Clive’s other previous roles include: Senior Vice President of Research and Development at PowderJect Pharmaceuticals plc. sold to Chiron in 2003, Chairman of the UK BioIndustry Association, Chairman of the Board of Directors of Crescendo Biologicals Limited and Chairman of the Board of Directors of Auralis Limited (acquired by ViroPharma Inc). Following post-doctoral roles and a period at Ciba-Geigy AG (now Novartis AG), Clive joined GlaxoWellcome plc. where he became UK Research Director. Clive is currently an Executive Chairman of the Board of Directors at C4X Discovery Holdings plc., Chairman of the Board of Directors at Touchlight Genetics Limited. Clive is a past Chairman of the Board of Directors of Calchan Ltd. Clive earned his B.Sc. and Ph.D. degrees in Pharmacology from University of Leeds.
Follow Clive Dix:
About C4X Discovery: C4X Discovery brings a new dimension to drug discovery. Using its unique NMR-based technique to determine 3D molecular.
Maria Chatzou Dunford
CEO and Co-Founder of Lifebit
Dr. Maria Chatzou, CEO of Lifebit, is a biotech innovator and a proud geek, expert in bioinformatics, medical informatics and high performance computing. She is also a passionate entrepreneur and has founded two companies, Innovation Forum Barcelona and Techstars-backed Lifebit. Prior to Lifebit, she was a researcher at the Centre for Genomic Regulation, in Barcelona, where she was designing and deploying tools and methods that facilitate the analysis of Big Biomedical Data, allow for biological discoveries, and promote personalised medicine. She was part of the developing team of Nextflow, a programming framework that is revolutionising the computational analysis of genomic data and setting the foundations for personalised medicine computational analyses. Maria is also a frequent industry speaker and has spoken in many international conferences on the subjects of docker containers, genomics workflows, the computational challenges of personalised medicine, AI and HPC in genomics, women in leadership, entrepreneurship, science ventures, among many other topics.
Follow Maria Chatzou Dunford:
About Lifebit: Lifebit CloudOS is the intelligent genomics platform that is the industry standard for unified, secure research over distributed big data.
Dipankar Bhattacharjee
President & CEO: Generics Europe of Teva Pharmaceutical Industries
Mr. Dipankar Bhattacharjee was appointed President and CEO, Generics Europe in April 2013. Mr. Bhattacharjee joined Teva as Chief Executive Officer, Teva UK Limited in 2009. Prior to joining Teva, he served 15 years at Bausch + Lomb in various senior roles, including Vice President, Commercial in both Europe and Asia-Pacific regions, and Corporate Vice President and President, Asia Pacific Region. Mr. Bhattacharjee began his career at Nestlé SA and Bank of America. Mr. Bhattacharjee received a BA in Economics from St. Stephens College, University of Delhi, and a Masters degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai.
Follow Dipankar Bhattacharjee:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Mark Livingstone
Chief Executive Officer of Pharmacy2U
Mark became Pharmacy2U’s CEO following a merger with ChemistDirect.co.uk in July 2016. An entrepreneurial business leader who has held many senior positions across retail and technology. Roles include co-founder and CEO of LOVEFiLM, worldwide Managing Director of Lego Interactive and one of the people behind the startup, Graze.com. With a passion for understanding how things work, Mark is a keen engineer who has rebuilt three 1950s Austin-Healeys.
Follow Mark Livingstone:
About ChemistDirect, Pharmacy2U: Pharmacy2U are the UK’s leading NHS approved online pharmacy and also provide a confidential private online doctor service.
Greg Bailey
CEO of Juvenescence
Dr. Gregory H. Bailey is a Managing Partner at Palantir Group, Inc. Dr. Bailey is the Co-founder of Ascent Healthcare Solutions; VirnetX Inc. (AMEX:VHC) and Duramedic Inc. He was also the initial public financier and an independent director of Medivation, Inc. (NASDAQ:MDVN), from 2005 to December 2012. Dr. Bailey served as the Managing Director and co-Head of Life Sciences at MDB Capital Group LLC from May 2004 to January 2007. Previously he served as Life Sciences Analyst at Participating Capital, Corp. He has served on the board of directors of multiple public companies. Dr. Bailey has Medical Doctorate from the University of Western Ontario and practiced medicine as an emergency physician for ten years.
Follow Greg Bailey:
About Juvenescence, Portage Biotech: Juvenescence is a biotech company that develops therapies and products to modify aging and help people live longer.
Robert Habib
Chief Executive Officer of MiNA Therapeutics
Follow Robert Habib:
About MiNA Therapeutics: MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms.
Anne Prener
President & CEO of Imbria Pharmaceuticals
Anne brings to Freeline over 25 years of experience in drug development and executive leadership across several therapeutic areas, with special focus on rare diseases and gene therapy. Anne most recently served as the CEO of Gyroscope Therapeutics, a preclinical gene therapy company focusing on ophthalmology, where she continues to serve as a non-executive Member of the Board. From 2014-2016, Anne was VP of Clinical Research Haematology and Global Therapeutic Area Head of Haematology in Baxalta, Boston, USA. In this role, she secured several new product approvals (US and EU). Before this, Anne held a number of senior leadership positions in a broad range of functional areas at Novo Nordisk, Denmark, leading global drug development programmes from research to commercialisation, and bringing several products to market globally. Anne has an MD from Copenhagen University and holds a PhD in Epidemiology.
Follow Anne Prener:
About Imbria Pharmaceuticals, Kaleido BioSciences: Imbria Pharmaceuticals is a biotechnology company with locations in San Diego, CA, and Boston, MA.
Hannah Sore
Founder and CEO of PharmEnable
Follow Hannah Sore:
About PharmEnable: PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery.
Dr Margaret Temple
CEO of Vitrology
Margaret Temple is a science and business graduate of Edinburgh University who joined the biotechnology industry in 1995. Following several commercial roles with Q- One Biotech Limited Margaret was appointed as a Board Director in 2002. In 2007 Margaret co -founded Vitrology Limited having secured funding from Archangels, and was appointed CEO in 2009. Vitrology was acquired by the Swiss multinational SGS in 2012, and a two year period of integration was completed at the end of 2014.
Follow Dr Margaret Temple:
About Vitrology: Vitrology is a biopharmaceutical contract testing organization in the biosafety testing sector of the pharmaceutical industry.
Zhangming Niu
Founder & CEO of MindRank AI
Follow Zhangming Niu:
About MindRank AI: MindRank is a developer of an AI-enabled drug-discovery platform intended to discover and develop next generation precision medicines.
Dennis O’Brien
CEO of Lucid Group Communications
Role To lead our team to be the best we can be and to make a difference to patients through healthcare. Pharmacology graduate. 13 years in pharma in a variety of roles. Co- founded Lucid in 2007 based on a passion to help pharma improve education to healthcare professionals. Background Favourite part of the job Helping to shape our future. Seeing and rewarding progress in line with our vision.
Follow Dennis O’Brien:
About Lucid Group Communications: Lucid offer talented writers an exclusive, tailor-made package to suit their individual needs and desires.
Yiannis Kiachopoulos
CEO, Co-Founder of Causaly
Follow Yiannis Kiachopoulos:
About Causaly: Causaly is teaching computers to read all knowledge in Biomedicine
Barney Gilbert
Founder, Co-CEO of Pando
Barney Gilbert worked in the NHS as a doctor before founding Pando, a healthtech company working to connect everyone working in healthcare. Listed in the UK’s Disruption50 Index for 2019. Forbes 30 Under 30 alum.
Follow Barney Gilbert:
About NHS England, Pando: Forward is now Pando! Pando is an essential tool for teamwork and secure collaboration in health and social care.
Tony de Fougerolles
Chief Executive Officer of Evox Therapeutics
Tony has been CEO of Evox Therapeutics since late 2017. He has 25 years of biotech R&D experience and has played a key role in developing and advancing three new drug modalities towards the market (mRNA, RNAi, Nanobodies). Previously, Tony was CSO of Ablynx, where he led the company’s non-clinical R&D operations and helped bring the 1st Nanobody drug, caplacizumab, to approval. Prior to Ablynx, Tony was the founding CSO at Moderna and pioneered modified mRNA as a new therapeutic modality for both rare diseases and as vaccines, including being the inventor of the mRNA chemistry and the foundational LNP formulations used in both the approved Moderna and Pfizer/BioNTech covid-19 vaccines. Prior to Moderna, Tony was among the first 6 employees at Alnylam and as VP Research helped develop RNAi as a new therapeutic modality, including overseeing the development of the now 1st approved LNP RNAi delivery system, and contributing to the development of several now approved RNAi drugs to treat life-threatening diseases. Tony has raised over $150m in equity financing, been the author on over $80m in grants, has over 60 scientific publications, and is an inventor on over 100 issued U.S. patents. He also serves on the Board of Walking Fish Therapeutics, is an advisor to and investor in multiple biotech companies, and is a Venture Partner at Ascension, a London-based venture capital firm. Lastly, he also volunteers his time with several non-profit organisations and charities. He earned his PhD in Immunology from Harvard University.
Follow Tony de Fougerolles:
About Evox Therapeutics: Evox Therapeutics is a biotechnology company that harnesses and engineer the natural trafficking capabilities of extracellular vesicles.
Ian Nicholson
Chief Executive Officer of F2G
Ian joined Advent in 2012 from Chroma Therapeutics Limited, a privately held oncology-focussed R&D company, where he served as Chief Executive Officer for eight years. Prior to joining Chroma, Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK’s largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. Ian has held a variety of senior commercial positions with Oxford Asymmetry International plc, Lonza AG and Amersham International plc and currently sits on the Boards of Consort Medical plc, Clinigen Group plc and is Non-Executive Chairman of Bioventix plc. Ian holds a B.Sc. (Hons.) degree from University College London and an MBA from Boston University. Ian is CEO of F2G Ltd and an advisor to NeRRe Therapeutics.
Follow Ian Nicholson:
About Advent Life Sciences, Amersham International, F2G: F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
Alex Zhavoronkov
Founder & Chief Executive Officer of Insilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery, and biomarker development. He is also the founder and CEO of Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (7th annual in 2020) at Basel Life, one of Europe’s largest industry events in drug discovery. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Follow Alex Zhavoronkov:
About Deep Longevity, Insilico Medicine: Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
Atul Devani
CEO of The GP Service
A serial entrepreneur, Atul has held a number of senior positions in software technology companies operating in various sectors including finance, mobile, telecoms, food & drink, health and pharmaceuticals.
He was founder and chief executive officer of AIM listed United Clearing Plc, which was sold to BSG in 2006 for £25m. He became CEO of BSG wireless which in 2008 was then sold to nasdaq listed Syniverse Tecnologies for $290m. Atul is currently CEO of leading online UK Healthcare provider “The GP Service” and Chairman of a Venture Capital Trust at Maven Capital and an investor in a number of private companies.
He is also a mentor of entrepreneurs at the Company of Information Technologists in the City of London. Atul has a First Class Honours Degree in Electronic Engineering from Bangor University.
Follow Atul Devani:
About The GP Service: The GP Service is a provider of online services for general medical consultations and prescriptions.
Andrew Hopkins
Co-Founder and CEO of Exscientia
Andrew spent 10 years at Pfizer, where he was responsible for establishing new research foci including the concepts of druggability and network pharmacology. Andrew has raised a total of $50 million for academic and commercial research activities in his continuing role as Chair of Medicinal Informatics at the University of Dundee. He is the author of some of the most highly cited papers in modern drug discovery.
Follow Andrew Hopkins:
About Exscientia, Kinetic Discovery Ltd.: Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
Daniel L. Cohen
CEO and Co-Founder of 3D Bio Holdings
Daniel L. Cohen is the Chief Executive Officer and Director at 3D Bio Holdings.
Follow Daniel L. Cohen:
About 3D Bio Holdings: 3D Bio Holdings is a company that specializes in regenerative medicine and devices.
Soren Krogsgaard Thomsen
Co-Founder, CEO and Managing Director of BioMe Oxford
Soren is a medical scientist at the University of Oxford, with a background in the natural sciences and genetics research. He previously worked as a consultant for pharma and OBR consulting, and has published on his experiences as an academic entrepreneur. Soren’s current research is focused on translating large-scale genetic data into mechanisms for disease to inform new therapeutic strategies. He dreams of one day enabling similar population-wide microbiome studies using the platform technology under development at BioMe Oxford Ltd.
Follow Soren Krogsgaard Thomsen:
About BioMe Oxford, Vertex Pharmaceuticals: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Edward Ungar
Co-Founder & CEO of Pharmacierge
Edward Ungar is a Co-founder at Pharmacierge.
Follow Edward Ungar:
About Pharmacierge: The free e-prescribing service chosen by Private GPs and Consultants to deliver medication to their patients nationwide
Jonathan O’Halloran
CEO of QuantuMDx Group
Inventor of QuantuMDx’s proprietary nucleic acid preparation, amplification and detection technology with over 12 years in scientific research, biotechnology & clinical laboratories.
Follow Jonathan O’Halloran:
About QuantuMDx Group: QuantuMDx is a medical devices company developing handheld and portable diagnostic, genomic sequencing, and proteomic platforms.
Graeme Neville Duncan
Chief Executive Officer of Advanz Pharma
Follow Graeme Neville Duncan:
About Advanz Pharma: ADVANZ PHARMA is a pharmaceutical company focused on serving the needs of patients and healthcare providers.
Kamil Tamiola
Chief Executive Officer of Peptone
I am a physicist, founder and CEO of Peptone Ltd.
Follow Kamil Tamiola:
About Peptone: Peptone is a UK-based startup that is helping pharmaceutical companies unravel the secrets of proteins.
Loubna Bouarfa
Co-Founder & CEO of OKRA Technologies
Loubna has won several awards and was recognised as a leading innovator by the MIT Technology Review in 2017. Beyond her business, Loubna has recently been appointed by the European Commission as a High-Level Expert on Artificial Intelligence. She will support the EU by developing recommendations on ethical, legal and societal issues related to AI, impacting the health, safety and freedom of the wider society. On a personal level, Loubna is a strong advocate for diversity and challenging the status quo. Having lived in Morocco, moving to the Netherlands at the age of 17, and later to the UK with a young family, she realised the power of remaining outside her comfort zone.
Follow Loubna Bouarfa:
About OKRA Technologies: OKRA is an AI analytics company for healthcare. We combine complex data sets, you get evidence-based insights and predictions in real time.
Martin-Immanuel Bittner
Co-Founder & CEO of Arctoris
Martin-Immanuel Bittner MD DPhil is a clinician-scientist and life sciences entrepreneur. He is a Rhodes scholar, an active member of several leading cancer research organisations, and an elected member of the Young Academy of the German National Academy of Sciences. Martin is a Co-Founder & CEO of Arctoris, the world’s first fully automated drug discovery platform.
Follow Martin-Immanuel Bittner:
About Arctoris: Arctoris is a tech-enabled platform company in biotechnology, combining robotics & data science to accelerate drug discovery.
Rasmus Hansen
Co-founder & CEO of Airfinity
Follow Rasmus Hansen:
About Airfinity: Airfinity is a science information and analytics company
Ronan Cunningham
Founder and Chief Executive Officer of BrainWaveBank
Ronan has more than 20 years of experience in advanced engineering and product development. He was one of the founding members of ATA Engineering, an award-winning San Diego-based engineering company specializing in development of innovative hardware and software technologies for the aerospace and defence industries. His roles have included Director of Business Development and Director of New Technology Development. He is an Entrepreneur-in-Residence with the Northern Ireland Science Park. His expertise is in early stage technology development, innovation strategy, and technology commercialisation. He holds an MS in Aeronautics and Astronautics from MIT.
Follow Ronan Cunningham:
About BrainWaveBank, Cumulus Neuroscience: BrainWaveBank makes it possible to measure and track brain activity and cognitive performance for anyone, anytime, anywhere.
Shravane Balabasqer
Founder | CEO of Carbon Analytics
Follow Shravane Balabasqer:
About Carbon Analytics: A granular asset focused carbon intelligence & offsetting platform for active industrial decarbonisation across the value chain.
Dimitri F Dimitriou
CEO of ImmuPharma
Dimitri F. Dimitriou has 25 years’ experience in the pharmaceutical and biotech industry. Prior to co-founding ImmuPharma, he was Senior Director, Worldwide Business Development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. He spent 8 years at Procter & Gamble in senior marketing, R&D and business development positions and began his career in marketing at Novartis (Sandoz) in 1987. He has a degree in biochemistry from Kings College, University of London and an MSc in pathology and toxicology from the Imperial College Medical School.
Follow Dimitri F Dimitriou:
About Dragon Finance, DyoDelta Biosciences, ImmuPharma: ImmuPharma plc is a United Kingdom-based drug discovery and development company. The Company is focused on developing drugs.
Olga Kubassova
Chief Executive Officer of IAG, Image Analysis Group
Olga Kubassova is the Founder and CEO at IAG, mage Analysis Group. Mathematician with 10+ years expertise in actively managing innovation in life science companies, asset positioning, strategy and capital rising. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.
Follow Olga Kubassova:
About Analytics Ventures, Bio Capital Impact Fund, European Commission, IAG, Image Analysis Group: IAG, imaging expert company helps to accelerate novel drug development by using the right analytical tools and modern trial infrastructure.
Ozgur Tuncer
CEO & Executive Director of Stablepharma Ltd
Ozgur Tuncer CEO & Executive Director – two decades of experience in the biopharmaceutical industry including working for blue chip companies such as Pfizer, IQVIA and Pharmacia. Most recently, he was Global Vice President in IQVIA, and strategic adviser to life sciences investors. In addition to his role in Stablepharma, Özgür is an Investment Partner with Ascension Ventures.
Follow Ozgur Tuncer:
About Stablepharma Ltd: An innovative Biotech, developing a wide range of reformulated thermostable and fridge free StablevaX vaccines
Jamie Denison-Pender
CEO of Prescient Healthcare Group
Jamie is Prescient Healthcare Group’s CEO and a career consultant, having spent more than 20 years growing and managing healthcare-focused consultancies. In 2007, he became managing director of a global competitive strategy consultancy and led the company’s transition from an industry generalist to a biopharmaceutical specialist. He rebranded the company to Prescient in 2010 and led a management buyout in 2014. Jamie remains actively involved with our clients, mainly focusing on strategic simulation workshops and mature brand strategies.
Follow Jamie Denison-Pender:
About Prescient Healthcare Group: Prescient Healthcare Group was founded in London in 1995, originally specializing in competitive insights.
Ibraheem Mahmood
CEO of DrugDev
Ibraheem Mahmood is the president and CEO of DrugDev.
Follow Ibraheem Mahmood:
About AMO Pharma, DrugDev: DrugDev is a cloud technology based solutions that enable better clinical trials.
Elliot Street
Co-Founder & CEO of Inovus Medical
Elliot studied medicine at the University of Manchester before completing his foundation training at the Oxford University Hospitals. Alongside his clinical commitments, he retains an active role in product development, bridging the gap between clinician and designer as well as running Inovus’ sales and marketing operations.
Follow Elliot Street:
About Inovus Medical, NHS England: The perfect package for any general surgical trainees or residents.
Javier Gonzalez-Zabaleta
Founder & CEO of Medimsight
Javier Gonzalez-Zabaleta was the main designer of the cloud model to bring worldwide medical imaging artificial intelligence solutions accessible to everyone. As one of the pioneers in this space, he has achieved a good experience in both market space and the technology. During last 10 years, he focused at the same time in business development, including direct communication with clinicians, and the understanding of the clinical trials market. Always open to talk, partnering and sharing knowledge. At the university, he studied computer science before made a master degree in computer vision making research in areas like multiple sclerosis and Alzheimer disease. Following his dream, empowering researchers and building super doctors, he has lived in Ponferrada, Madrid and now in London.
Follow Javier Gonzalez-Zabaleta:
About FundRx, Medimsight: Medical image triage and biomarkers analysis for precision medicine.
Eliot Forster
CEO of F-star Therapeutics
Eliot Forster is Chief Executive Officer at F-star Therapeutics.
Follow Eliot Forster:
About F-star Therapeutics: F-star is developing a pipeline of novel bispecific antibodies with a therapeutic focus in immuno-oncology and oncology.
Peter Widdowson
Founder & CEO of Quethera
Peter Widdowson has over 30 years of drug discovery experience during which he has worked on a number of small molecule, protein and gene therapy approaches to managing disease. He has a background in researching therapies for indications as diverse as ophthalmic, neurological and psychiatric disorders, type-2 diabetes, oncology, gastrointestinal motility disorders and inflammatory conditions encompassing inflammatory bowel disease and rheumatoid arthritis. He has held a number of senior scientific roles within Servier (Research Group Leader), AstraZeneca (Senior Scientist and Project Research Manager), Pfizer (Senior Scientist and Project Research Manager), OSI Pharmaceuticals (Director of Pharmacology) and most recently, whilst Head of Preclinical Development at Oxford BioMedica was responsible for overseeing and managing the development of three lentiviral vector gene therapies for wet age-related macular degeneration, Stargardt disease and Usher 1B syndrome which are all currently in Phase I/II clinical development. Dr. Widdowson has experience in all aspects of preclinical and early stage development from animal model proof-of-concept studies to clinical trial design and biomarker identification. Widdowson holds a Bachelor of Science degree in human Physiology from Newcastle University and a PhD in Neuropharmacology from Manchester University.
Follow Peter Widdowson:
About Ikarovec, Quethera: Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases.
Mark Larkin
CEO and Founder of Vitaccess
Mark Larkin founded Vitaccess in 2017, after more than 15 years in consultancy, with the aims of harnessing the power of digital technology to better represent the voice of patients in drug development and market access. Mark has a BA, MA and PhD from the University of Cambridge, UK.
Follow Mark Larkin:
About Vitaccess: Digital healthcare company providing biopharma clients with real-time insights into patients’ lives via innovative global studies
Derek Gilchrist
Co Founder & CEO of Causeway Therapeutics
Derek is a principal investigator at the University of Glasgow and leads the scientific and technical development of TenoMiR™.
Follow Derek Gilchrist:
About Causeway Therapeutics, University of Glasgow, University of Glasgow: A bio pharmaceutical spin out emerging.
Duncan Hall
Founder and CEO of Triumph Research Intelligence
Duncan has over fifteen years of consultancy experience, thirteen of which have been within clinical R&D in both CRO and Pharma businesses. Duncan started Triumph in 2002 with the aim of building a global business which would be focused in improving the delivery, quality and value of clinical systems. Duncan now takes a primarily strategic role in TRI, but still performs client delivery roles where possible.
Follow Duncan Hall:
About Triumph Research Intelligence: Triumph Research Intelligence is a risk-Based Monitoring Company.
Fabrice Chartier
Group Chief Executive Officer of Simbec-Orion Group
Follow Fabrice Chartier:
About Simbec-Orion Group, Simbec-Orion Group: They offer specialist expertise in oncology, rare & orphan diseases, respiratory, dermatology and infectious vaccines & diseases.
Malcolm Weir
Founder & CEO of Heptares Therapeutics
Former Visiting Professor of Biochemistry at Imperial College, London. Former Head of the Molecular Sciences Division of Glaxo Wellcome Inc. (present Glaxo Smithkline plc.) Former CEO of Inpharmatica Ltd.（present Galapagos NV). Founder and CEO of Heptares Therapeutics Ltd.
Follow Malcolm Weir:
About Heptares Therapeutics, Sosei Group: Heptares Therapeutics develops novel, small-molecule drugs for G-protein-coupled receptors (GPCRs).
Allison Jeynes-Ellis
Co-Founder & CEO of Avillion
Over 20 years of senior leadership experience in the pharmaceutical industry. Significant global drug development experience and successful EU and US drug approvals across a range of therapeutic areas. Leadership of global clinical development teams for Phase 3, including CRO selection and management. Strong networks within the pharma industry and relevant regulatory bodies
Follow Allison Jeynes-Ellis:
About Avillion: Avillion LLP, a London, UK-based company that focuses on clinical co-development of therapeutics.
Kadem Al-Lamee
CEO of Arterius
Kadem Al-Lamee, CEO, Arterius Limited, was a co-founder of PolyBioMed Limited in 1996, serving as Technical Director before becoming Managing Director in 2001, when PolyBioMed was acquired by Lombard Medical Technologies. PolyBioMed was recently purchased by Bayer Materials Science. Dr Al-Lamee was integral to the development of the business throughout its history, including strategic development, fund-raising, technical development and the establishment of its intellectual property portfolio. Previously he was Principal Scientist in polymer chemistry for Innovative Technologies plc, managing research and development programmes in areas including wound dressings and coated urinary catheters. Dr Al-Lamee has extensive research and teaching experience with an MSc and PhD in Polymer Chemistry from the University of Liverpool. He has over 30 years experience in Biomaterials and Medical Devices, has published over 50 papers in international journals and holds 25 granted patents/patent applications. Dr Al-Lamee’s main interests are biomaterials, surface modifications and the coating of materials commonly used in medical devices, drug delivery systems, hydrogels for medical applications, cardiovascular devices, wound-care products, urology and tissue engineering devices. He has been successfully awarded many grants from the UK’s DTI, the Innovate UK, Yorkshire Forward, and European Commission for the research and development of healthcare projects.
Follow Kadem Al-Lamee:
About Arterius: Arterius developing a novel next-generation polymer-based Bio-resorbable Coronary Scaffold (BRS), more commonly known as a ‘stent’.
Jennifer Barnett
CEO of Monument Therapeutics
Follow Jennifer Barnett:
About Cambridge Cognition, Monument Therapeutics: Monument Therapeutics develops products to treat serious diseases of the central nervous system.
Michael Chen
Co-founder and CEO of Nuclera
Michael Chen is the Co-founder and CEO at Nuclera.
Follow Michael Chen:
About Nuclera: Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis.
Ben Pellegrini
Chief Executive Officer of Intellegens
Follow Ben Pellegrini:
About Intellegens: Cambridge spin out using Deep Learning to train on big, incomplete data. Currently working in drug discovery and material design.
Peter Kennerley
Chief Executive Officer & Founder of Emas Pharma
Peter joined the pharmaceutical industry in 1987 after several years in the NHS as an anaesthetist. Since then, he has worked in senior positions for major as well as small Pharma companies, with duties ranging from drug development to medical affairs and he has brought several products to market, both as blockbusters and as niche products. Since establishing Emas, he has chaired expert panels, established drug safety processes and overseen successful regulatory procedures for a range of products from radiolabelled monoclonal antibodies to mast cell histamine release inhibitors and from glucoside inhibitors to proton pump inhibitors. He retains a determination that Emas should avoid the usual service company clichés and simply demonstrate its worth through the highest possible quality support at a competitive cost.
Follow Peter Kennerley:
About Emas Pharma: Emas Pharma provides pharmaceutical and device development services worldwide and specializes in partnering with specialist pharma.
Sarah Howell
Chief Executive Officer of Arecor
Sarah Howell joined Arecor Limited as Chief Executive Officer in 2015.
Follow Sarah Howell:
About Arecor: Arecor is a leader in developing superior biopharmaceuticals through the application of its innovative formulation technology platform.
Michael Hunter
CEO Designate of Viatem
Michael Hunter is a Co-Founder & CEO at Orca Pharmaceuticals.
Follow Michael Hunter:
About Orca Pharmaceuticals, Viatem: Viatem is an University of Birmingham Spinout company working to exploit the therapeutic potential of PEPITEM.
Dan Hydes
CEO & Co-Founder of IgniteData
Follow Dan Hydes:
About IgniteData: IgniteData is the company shaping the future of clinical trials through its innovative digital health platform, Archer.
John Ridden
Chief Executive Officer of Blueberry Therapeutics
An experienced Drug Discovery Scientist and Leader with 20 years of experience. Held leadership positions in AstraZeneca and Pfizer leading functions focused on both early and late stage preclinical research in oncology, inflammation, metabolism and dermatology. My current focus is on the use of nanomedicines to treat diseases with significant unmet need. My professional ambition: To build a successful drug company with the skills base and resources to treat infectious disease by developing new antifungals and new antibiotics. Specialties: Building teams, leadership, creativity & Innovation, strategy and drug hunting.
Follow John Ridden:
About Blueberry Therapeutics, Tecrea: Blueberry Therapeutics focuses on developing medicines for inflammatory and infectious diseases.
Andrew Gardiner
Chief Executive Officer of Libero Pharma
Andrew Gardiner is Founder & CEO at Syntropharma.
Follow Andrew Gardiner:
About Libero Pharma, Syntropharma: Libero Pharma was established by a group of entrepreneurs to bring a transdermal naltrexone patch.
Jeff Moore
Founder & CEO of Curileum Discovery Ltd
Follow Jeff Moore:
About Curileum Discovery Ltd: Curileum Discovery Ltd is a drug target discovery company in London targeting defective stem cells underpinning serious GI diseases
Stephen A. Stamp
Chief Executive Officer of Midatech Pharma
Stephen Stamp is responsible for all financial matters at Assurex Health, including financing strategy and implementation, accounting, tax, mergers & acquisitions, and government contracting. Stephen brings to Assurex Health nearly 30 years of experience in finance, accounting, business development and operations. He has worked in multiple public and venture-backed companies both in the US and the UK, including business to consumer (B2C), business to business (B2B), and pharmaceutical industries. Stephen has served as Chief Financial Officer of EZCORP, Inc., a publicly-traded consumer financial services company; Chief Operating Officer, Chief Financial Officer, and Executive Vice President Business Development at Xanodyne Pharmaceuticals, Inc., a specialty pharmaceutical company; Group Finance Director at Regus PLC, a publicly-traded company that provides serviced office accommodations in business centers worldwide; and as Group Finance Director at Shire PLC, a publicly-traded UK specialty pharmaceutical company focused on ADHD and other specialty medications. Earlier in his career, Stephen was an investment banker with Lazard in London and worked for KPMG, also in London, where he qualified as a Chartered Accountant. Stephen received his BA in economics from the University of Manchester.
Follow Stephen A. Stamp:
About Assurex Health, Ergomed, EUSA Pharma, Midatech Pharma: Midatech Pharma a particle engineering with an emphasis on microfluidics and drug delivery.
STEVE HOLMES
CEO and Founder of Capella BioScience
Follow STEVE HOLMES:
About Capella BioScience: Capella Bioscience engages in the discovery and development of monoclonal antibodies.
Ross Burn
Chief Executive Officer of CatSci
Ross completed a MSci in Forensic and Analytical Chemistry at the University of Strathclyde, Glasgow. He completed his PhD in 2007 on the use of chromatography, electrophoresis and mass spectrometry for mining the human plasma proteome for biomarkers of disease with Prof. David Perrett at Barts and the London, Queen Mary’s School of Medicine, University of London. In 2007, he joined AstraZeneca as an Analytical Chemist to support the AstraZeneca Catalysis Facility and develop techniques to improve process understanding.
Follow Ross Burn:
About CatSci: CatSci provides innovative process research and development services to emerging, mid-sized and large pharma.
Daljit Cheema
Founder & CEO of PHARMASEAL
Daljit Cheema is Founder & CEO at PHARMASEAL.
Follow Daljit Cheema:
About PHARMASEAL: PHARMASEAL is developing the first B2B control platform for biopharmaceutical companies to manage their enterprise clinical trials.
Frank F. Craig
CEO of Sphere Fluidics
Dr Frank F. Craig has around 15 years of international, general management experience gained from GlaxoSmithKline, Amersham Biosciences (as a Vice-President of R&D) and several start-up firms. He was responsible for managing product development of Green Fluorescent Protein (first identified by the 2008 Nobel Prize Winners for Chemistry) and many other cell-based products and services for the Life Sciences industry. Frank was a (co)-Founder of Aurora Biosciences (San Diego, USA), which had a peak market cap. of £1.8 billion and was acquired by Vertex Pharmaceuticals for £420 million. He was also a co-Founder and CEO of Smart Holograms (Cambridge, UK) – named as the UK’s Fastest Growing Company. Frank has raised £22 million in Private Equity, £25 million via an IPO on NASDAQ and has delivered many commercial partnerships with global Life Sciences and Energy firms – resulting in recorded deal values of £180 million. He has been a Board Director of Smart Holograms and TekCel (Hopkinton, USA), and helped form Sphere Fluidics before becoming its CEO in May 2010. He has a PhD in Cell Biology and Microbiology from Glasgow University and an MBA from Warwick Business School.
Follow Frank F. Craig:
About BioChannel Partners, Sphere Fluidics: Sphere Fluidics develops products for use in single cell analysis and characterization, and provides associated collaborative R&D services.
Simon Haworth
Chief Executive Officer of Intelligent OMICS
Follow Simon Haworth:
About Dynasty Biotechnology and the Sino-UK Fund, Intelligent OMICS: Intelligent OMICS is a translational company that converts big data into biological intelligence.
Hakim Yadi
CEO & Co-Founder of Closed Loop Medicine
Hakim Yadi is the CEO and Co-Founder at Closed Loop Medicine.
Follow Hakim Yadi:
About : Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians
Joanna Burnett
Co-founder and CEO of GPrX Data
Follow Joanna Burnett:
About GPrX Data: GPrX Data translates NHS practice level prescribing data into easily-reviewed intelligence.
Manoranjan Das
Co-founder and CEO of Allot
Founder and CEO Manoranjan Das has more than 22 years of experience working in the IT sector at a global level. He established Allot Limited after realising that there was a need in the industry for a straightforward and professional business intelligence provider which fully utilises cloud computing. He decided that he could use his own expertise to help other businesses realise their full potential by making their data and information processes as efficient as possible. Over the course of his career, Manoranjan has lived and worked in the USA, Taiwan and India, before finally settling in the UK. He has setup business intelligence practices for a large number of organisations with P&L responsibilities. This included creating, developing and delivering multiple and multifaceted data warehouse, data migration, data quality and business intelligence solutions within the utility, manufacturing, banking, insurance, retail and healthcare sectors. His areas of expertise include: data management; Big Data; BI competency; data governance; and data migration; along with an expert understanding of various products and technology. Manoranjan has worked closely with a number of major international corporations, including British Gas, General Electric, Diageo, Lloyds Bank, AEGON, Deutsche Bank, Prudential, Aviva, Prudential Financial, Motorola, TSMC, BP, News International, the NHS, Eli Lilly and BOOTS, helping them to complete their technology-driven organisational transformation. Manoranjan is highly qualified in his field, holding a post-graduate diploma in planning and a Bachelor’s degree in civil engineering. He is also a chartered member of the British Computer Society.
Follow Manoranjan Das:
About Allot: Data analytics startup that helps pharmaceutical companies market launch and commercialise their drugs.
Matt Lowe
CEO and founder of performance.io
Networker, broker, influencer, and experienced digital ambassador and communications advocate, Matt is passionate about accelerating growth and innovation in healthcare through use of new technologies and modern day communications disciplines. He provides high-end consultancy to many C-suite executives and fortune 500 healthcare companies, building integrated brand engagement strategies on forensic insights that deliver measurable outcomes impacting the lives of millions. A judge on several awards networks, a regular contributor to many leading publications and regular keynote speaker he also provides advice for a number of start-ups, is a faculty member at BartsXMedicine and sits on the Advisory Board for Webit Health, the single most influential digital economy, tech, policy & startup event for Europe in 2018. Having joined the Board of an integrated network group, in 2015 he founded and launched the world’s first health specialist SEO and SEM company out of London and NY. Passionate about mental wellness, people and productivity he is a Board member for the Hatch supported PeaceLove Foundation, and through his Marketing agency he provides pro bono solutions to ensure as many people as possible help create peace of mind. With faith in people, technology and the marriage of the two, Matt also advises for Artmatr, a pioneering company that are developing next level technologies that sit at the nexus of art, engineering and robotics. Artmatr have several labs and incubators that allow engineers and artists to collaborate to find new solutions in health, art and engineering that are the driving force for the next great crossover of our time, (digital art and physical art) and are helping people with disabilities to express their creativity through technology.
Follow Matt Lowe:
About performance.io: performance.io is a performance marketing agency focused on health & tech.
Lisa LM Anson
Chief Executive Officer of Redx Pharma
Lisa Anson is Chief Executive Officer of Redx Pharma plc, appointed 1 June 2018. Lisa has been President of AstraZeneca UK since 2012 and has significant leadership experience in pharmaceuticals. Over a 20 year career at AstraZeneca plc, Lisa has held a number of senior management roles in both the US and the UK including Global Vice President, Oncology and as Vice President of emerging brands where she worked closely with the Research and Development teams. Lisa holds an MBA (awarded with distinction) from INSEAD, France and a First Class honours degree in Natural Sciences from Cambridge University in the UK. Upon graduating she joined KPMG in London as a management consultant and then moved to California where she worked for Salick Health Care (now Aptium), a California based cancer disease management company, prior to joining Zeneca Pharmaceuticals (USA) in 1998 as a business development manager. Lisa is President of the Association of the British Pharmaceutical Industry (ABPI) a position from which she will step down in 2018. She has been a Board member of the ABPI since 2012 where she has chaired a number of UK industry committees and worked closely with Government. Lisa currently lives in Cheshire with her husband Andy and her three children.
Follow Lisa LM Anson:
About Redx Pharma: Redx Pharma is a drug discovery and development company.
Stuart Young
Chief Executive Officer of Panthera Biopartners
Follow Stuart Young:
About Panthera Biopartners: Panthera Biopartners helps pharmaceutical and contract research organizations to find the patient for clinical trials.
Andrew Hook
Founder & CEO of Tracepad
Follow Andrew Hook:
About Tracepad: Tracepad develops innovative solutions for pharmaceutical provenance.
Alastair Smith
CEO of Avacta Group
Follow Alastair Smith:
About Avacta Group: Avacta Group plc is a provider of technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics.
John Dawson
CEO & Founder of Alliance Pharmaceuticals
Follow John Dawson:
About Alliance Pharmaceuticals: Alliance’s principal activities are the acquisition and licensing of mature pharmaceutical products and the marketing of those products.
